Citation tools
"A randomised, factorial phase II study to determine the optimal dosing regimen for 68Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours." Journal of Nuclear Medicine
(2021):
jnumed.121.261936.
Web. 28 Mar. 2024.